Vallance P., Leone A., Calver A., Collier J., Moncada S.Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure . Lancet1992; 339: 572-75.
2.
Miyazaki H., Matsuoka H., Cooke JPEndogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis . Circulation1999; 99: 1141-46.
3.
Zoccali C., Bode-Böger SM, Mallamaci F. et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD) . Lancet2001; 358: 2113-17.
4.
Valkonen VP, Päivä H., Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet2001; 358: 2127-28.
5.
Dayoub H., Achan V., Adimoolam S. et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation2003; 108: 3042-47.
6.
Böger RHThe emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res2003; 59: 824-33.
7.
Cooke JPAsymmetrical dimethylarginine: the Über marker? Circulation2004; 109: 1813-18.
8.
Vallance P., Leiper J.Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol2004; 24: 1023-30.
